Search hospitals > Quebec > MONTREAL
Jewish General Hospital
Claim this profileMONTREAL, Quebec H3T 1E2
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Prostate Cancer
Conducts research for Lymphoma
527 reported clinical trials
31 medical researchers
Summary
Jewish General Hospital is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Breast Cancer, Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Lymphoma and other specialties. Jewish General Hospital is involved with conducting 527 clinical trials across 520 conditions. There are 31 research doctors associated with this hospital, such as Cristiano Ferrario, MD, Dr. Tamim Niazi, MDCM, Petr Kavan, Dr, and Wilson Miller.Area of expertise
1Breast Cancer
Global LeaderStage IV
Stage III
HER2 negative
2Cancer
Global LeaderStage IV
HER2 positive
Stage III
Top PIs
Cristiano Ferrario, MDJewish General Hospital8 years of reported clinical research
Studies Breast Cancer
Studies Prostate Cancer
13 reported clinical trials
38 drugs studied
Dr. Tamim Niazi, MDCMJewish General Hospital, McGill University4 years of reported clinical research
Studies Prostate Cancer
Studies Cardiovascular Disease
10 reported clinical trials
28 drugs studied
Petr Kavan, DrJewish General Hospital2 years of reported clinical research
Studies Pancreatic Cancer
Studies Colorectal Cancer
10 reported clinical trials
39 drugs studied
Wilson MillerJewish General Hospital2 years of reported clinical research
Studies Melanoma
Studies Non-Small Cell Lung Cancer
7 reported clinical trials
11 drugs studied
Clinical Trials running at Jewish General Hospital
Breast Cancer
Cancer
Blood Clot
Colorectal Cancer
Deep Vein Thrombosis
Lymphoma
Non-Small Cell Lung Cancer
Tumors
Melanoma
Blood Cancers
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Recruiting4 awards Phase 3
PF-07220060 + Fulvestrant
for Advanced Breast Cancer
The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body. This study is seeking female and male participants who: * are 18 years of age or older; * are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; * have advanced or metastatic breast cancer after taking other treatments before this study; * have not taken or need to take medications that are not allowed by the study protocol; * do not have any medical or mental conditions that may increase the risk of study participation. Half of the participants will take PF-07220060 two times daily by mouth along with fulvestrant. Fulvestrant will be given as a shot into the muscle. The other half will take the study doctor's choice of treatment which can either be: * Fulvestrant alone taken as shot into the muscle. * Everolimus along with exemestane taken once daily by mouth. This study will compare the experiences of participants receiving the study medicine plus fulvestrant to those who are receiving the study doctor's choice of treatment. This will help decide if the study medicine is safe and effective. Participants will receive study treatment and/or will be in the study until: * imaging scans (such as an MRI and/or CT) show that their cancer is getting worse. * the study doctor thinks the participant is no longer benefitting from the study medicine. * has side effects that become too severe. A side effect is a reaction (expected or unexpected) to a medicine or treatment you take. * the participant chooses to stop taking part.
Recruiting2 awards Phase 3
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Jewish General Hospital?
Jewish General Hospital is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Breast Cancer, Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Lymphoma and other specialties. Jewish General Hospital is involved with conducting 527 clinical trials across 520 conditions. There are 31 research doctors associated with this hospital, such as Cristiano Ferrario, MD, Dr. Tamim Niazi, MDCM, Petr Kavan, Dr, and Wilson Miller.
Where is Jewish General Hospital located?
**Directions to Jewish General Hospital, Montreal:**
- **By Car:** Take I-5 North to Exit 66, then follow the signs for the hospital on Ch de la Côte-Ste-Catherine.
- **By Public Transportation:** Take the LIGNE 2 - ORANGE metro line to Station Plamondon. The hospital is a 13-minute walk from the station.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Jewish General Hospital, contact the Financial Assistance department at 514-340-8222, extension 22230, for details on qualification and application. For insurance inquiries, use the hospital's main line at 514-340-8222. Questions regarding fees for medical services should be directed to the Patient Account Office, available at the same contact number.
What insurance does Jewish General Hospital accept?
The Jewish General Hospital, located in Montreal, Quebec, Canada, is a key institution within the Integrated Health and Social Services University Network for West-Central Montreal (CIUSSS West-Central Montreal). Residents of Quebec with private insurance are required to present proof of insurance coverage during hospitalization. For specific insurance plan acceptance and coverage verification, it is advised to directly contact the hospital or your insurance provider.
What awards or recognition has Jewish General Hospital received?
The Jewish General Hospital, located in Montreal, Quebec, is renowned for its pioneering research in cancer treatment at the Segal Cancer Centre. It houses the Lady Davis Institute, one of Canada's leading biomedical research institutions, with expertise in cancer, aging, epidemiology, AIDS, cardiovascular disease, genetics, and more. This hospital is acknowledged globally for its contributions to various fields, including emergency medicine, nephrology, and the psychosocial aspects of illness.